Children with perinatally acquired human immunodeficiency virus (PHIV) face a lifetime of combination antiretroviral treatment that often includes dolutegravir (DTG). DTG, an integrase strand inhibitor that has been linked to weight gain in adults, is increasingly being used in children. Understanding its potential short- and long-term sequelae in children is critically important. We report a case of excessive weight gain in a child with PHIV on DTG and provide a brief literature review.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of the Pediatric Infectious Diseases Society|
|State||Published - Mar 1 2021|
- human immunodeficiency virus (HIV)
- weight gain
ASJC Scopus subject areas